|
PT2057156T
(pt)
*
|
2006-08-23 |
2017-05-04 |
Kudos Pharm Ltd |
Derivados de 2-metilmorfolina pirido-, pirazo- e pirimidopirimidina como inibidores de mtor
|
|
JP2010521450A
(ja)
*
|
2007-03-16 |
2010-06-24 |
アクテリオン ファーマシューティカルズ リミテッド |
Ｓ１ｐ１／ｅｄｇ１受容体アゴニストとしてのアミノ−ピリジン誘導体
|
|
US20080234262A1
(en)
*
|
2007-03-21 |
2008-09-25 |
Wyeth |
Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
|
|
US9029411B2
(en)
|
2008-01-25 |
2015-05-12 |
Millennium Pharmaceuticals, Inc. |
Thiophenes and uses thereof
|
|
AU2009248993C1
(en)
*
|
2008-05-23 |
2013-10-03 |
Wyeth Llc |
Triazine compounds as PI3 kinase and mTOR inhibitors
|
|
UY32138A
(es)
|
2008-09-25 |
2010-04-30 |
Boehringer Ingelheim Int |
Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
|
|
US9090601B2
(en)
|
2009-01-30 |
2015-07-28 |
Millennium Pharmaceuticals, Inc. |
Thiazole derivatives
|
|
US9139589B2
(en)
|
2009-01-30 |
2015-09-22 |
Millennium Pharmaceuticals, Inc. |
Heteroaryls and uses thereof
|
|
UY32470A
(es)
|
2009-03-05 |
2010-10-29 |
Boehringer Ingelheim Int |
Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
|
|
US8242260B2
(en)
|
2009-08-28 |
2012-08-14 |
Novartis Ag |
Compounds and compositions as protein kinase inhibitors
|
|
WO2011067356A2
(en)
|
2009-12-03 |
2011-06-09 |
Novartis Ag |
Polymorphs of a mek inhibitor
|
|
WO2011067348A2
(en)
|
2009-12-03 |
2011-06-09 |
Novartis Ag |
Mek inhibitor salts and solvates thereof
|
|
SG183155A1
(en)
|
2010-02-03 |
2012-09-27 |
Signal Pharm Llc |
Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
|
|
GB201004200D0
(en)
*
|
2010-03-15 |
2010-04-28 |
Univ Basel |
Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
|
|
US8748428B2
(en)
|
2010-03-30 |
2014-06-10 |
Novartis Ag |
Use of a PKC inhibitor
|
|
KR101830455B1
(ko)
|
2010-04-13 |
2018-02-20 |
노파르티스 아게 |
시클린 의존성 키나제 ４ 또는 시클린 의존성 키나제 （ｃｄｋ４／６） 억제제 및 ｍｔｏｒ 억제제를 포함하는 암 치료를 위한 조합물
|
|
KR20130048293A
(ko)
|
2010-06-25 |
2013-05-09 |
노파르티스 아게 |
단백질 키나제 억제제로서의 헤테로아릴 화합물 및 조성물
|
|
WO2012021611A1
(en)
|
2010-08-11 |
2012-02-16 |
Millennium Pharmaceuticals, Inc. |
Heteroaryls and uses thereof
|
|
US8586604B2
(en)
|
2010-08-20 |
2013-11-19 |
Boehringer Ingelheim International Gmbh |
Inhibitors of the microsomal prostaglandin E2 synthase-1
|
|
US8759537B2
(en)
|
2010-08-20 |
2014-06-24 |
Boehringer Ingelheim International Gmbh |
3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
|
|
US8466186B2
(en)
|
2010-12-10 |
2013-06-18 |
Boehringer Ingelheim International Gmbh |
Compounds
|
|
UY33779A
(es)
|
2010-12-10 |
2012-07-31 |
Boehringer Ingelheim Int |
?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
|
|
US8486968B2
(en)
|
2010-12-10 |
2013-07-16 |
Boehringer Ingelheim International Gmbh |
Compounds
|
|
US20130158023A1
(en)
|
2011-08-03 |
2013-06-20 |
Signal Pharmaceuticals, Llc |
Identification of gene expression as a predictive biomarker for lkb1 status
|
|
AU2012313888B2
(en)
|
2011-09-27 |
2016-03-31 |
Novartis Ag |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
|
|
US9403829B2
(en)
*
|
2011-12-02 |
2016-08-02 |
Signal Pharmaceuticals, Llc |
Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their use
|
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
|
JP6120311B2
(ja)
*
|
2013-02-12 |
2017-04-26 |
学校法人銀杏学園 |
ポリフェノール化合物
|
|
KR20150131224A
(ko)
|
2013-03-14 |
2015-11-24 |
노파르티스 아게 |
돌연변이 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
|
|
US9505764B2
(en)
|
2013-04-17 |
2016-11-29 |
Signal Pharmaceuticals, Llc |
Treatment of cancer with dihydropyrazino-pyrazines
|
|
CA2908957C
(en)
|
2013-04-17 |
2021-05-18 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
|
|
EA030726B1
(ru)
|
2013-04-17 |
2018-09-28 |
СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
ФАРМАЦЕВТИЧЕСКИЕ СОСТАВЫ, СПОСОБЫ, ТВЕРДЫЕ ФОРМЫ И СПОСОБЫ ПРИМЕНЕНИЯ, ОТНОСЯЩИЕСЯ К 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1H)-ОНУ
|
|
AU2014254059B2
(en)
|
2013-04-17 |
2019-06-06 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a TOR kinase inhibitor and a cytidine analog for treating cancer
|
|
CA2908353C
(en)
|
2013-04-17 |
2021-11-02 |
Signal Pharmaceuticals, Llc |
Treatment of cancer with dihydropyrazino-pyrazines
|
|
HK1221168A1
(zh)
|
2013-04-17 |
2017-05-26 |
西格诺药品有限公司 |
用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法
|
|
MX368286B
(es)
|
2013-04-17 |
2019-09-27 |
Signal Pharm Llc |
Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
|
|
HK1223286A1
(zh)
|
2013-05-29 |
2017-07-28 |
西格诺药品有限公司 |
7-(6-(2-羟基丙-2-基)吡啶-3-基)-1-((反式)-4-甲氧基环己基)-3，4-二氢吡嗪并[2，3-b]吡嗪-2(1h)-酮的药物组合物、其固体形式及它们的使用方法
|
|
RU2016136091A
(ru)
*
|
2014-02-14 |
2018-03-19 |
Дзе Юниверсити Оф Бритиш Коламбиа |
Соединения, воздействующие на днк-связывающий домен (dbd) андрогенового рецептора человека, в качестве терапевтических средств, а также способы их применения
|
|
JP2017511367A
(ja)
|
2014-04-16 |
2017-04-20 |
シグナル ファーマシューティカルズ，エルエルシー |
１−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン及び共形成物を含む固体形態、その組成物及び使用方法
|
|
NZ714742A
(en)
|
2014-04-16 |
2017-04-28 |
Signal Pharm Llc |
Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
|
|
ES2959860T3
(es)
|
2017-06-22 |
2024-02-28 |
Celgene Corp |
Tratamiento del carcinoma hepatocelular caracterizado por la infección por el virus de la hepatitis B
|
|
US20240208964A1
(en)
*
|
2020-06-03 |
2024-06-27 |
Pyridopyrimidines And Methods Of Their Use |
Pyridopyrimidines and methods of their use
|
|
WO2025012643A1
(en)
|
2023-07-11 |
2025-01-16 |
Tay Therapeutics Limited |
Compounds comprising a naphthyridine or pyridopyrimidine core as ptc read-through agents
|